LYMZENTY
Live / Allowed — Notice of allowance issued (as of 10 Feb 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 06 Mar 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98435992
- Mark type
- Stylized text
- Filed
- 06 Mar 2024
- Published for opposition
- 13 May 2025
- Attorney of record
- Marilyn F. Kelly
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs being pharmaceutical preparations for the treatment of cancer; anticoagulants; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; Pharmaceutical preparations for human use for the treatment of cystic fibrosis
Owner
- Celgene Corporation, Princeton, NJ, US
- Celgene Corporation, Princeton, NJ, US
Prosecution history
- 10 Feb 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 10 Feb 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 10 Feb 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 10 Feb 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 02 Jan 2026 — TTAB RELEASE CASE TO TRADEMARKS
- 02 Jan 2026 — OPPOSITION TERMINATED NO. 999999
- 02 Jan 2026 — OPPOSITION DISMISSED NO. 999999
- 12 Jul 2025 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 10 Jul 2025 — OPPOSITION INSTITUTED NO. 999999
- 06 Jun 2025 — EXTENSION OF TIME TO OPPOSE RECEIVED
- 13 May 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 13 May 2025 — PUBLISHED FOR OPPOSITION
- 07 May 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 07 Apr 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED